Xconomy: East Coast Biotech Roundup: Genocea, Eleven, NIH
Summary
Those stories and more below: —Cambridge, MA-based vaccine developer Genocea Biosciences (NASDAQ: GNCA) was the first local biotech to price this week, and it got a lukewarm response from Wall Street.—Merck was part of another big partnership this week as well, announcing plans to join with Pfizer, Thousand Oaks, CA-based Amgen (NASDSAQ: AMGN), and Wilmington, DE-based Incyte (NASDAQ: INCY) to run several combination studies using its experimental cancer antibody drug MRK-3475.— Biogen was cleared this week to sell its oral multiple sclerosis drug, dimethyl fumarate (Tecfidera), in Europe.—Longtime Genzyme executive Frederic Chereau is taking flight for San Diego, where he’ll become the president and chief operating officer of aTyr Pharma.When Pervasis was acquired by Shire in 2012, Chereau stayed on board and was in charge of the company’s global angioedema franchise.
Classifications
AskAI Classifications
LabelsLinked Companies
